These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 29086602)

  • 1. The use of cefepime as a carbapenem-sparing antibiotic for treating uncomplicated acute pyelonephritis caused by extended-spectrum β-lactamase producing Escherichia coli.
    Suh JW; Yang KS; Kim SB; Kim JH; Sohn JW; Kim MJ; Yoon YK
    Infect Dis (Lond); 2018 Mar; 50(3):241-244. PubMed ID: 29086602
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
    Yoon YK; Kim JH; Sohn JW; Yang KS; Kim MJ
    Int J Antimicrob Agents; 2017 Apr; 49(4):410-415. PubMed ID: 28263710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
    Park SH; Choi SM; Chang YK; Lee DG; Cho SY; Lee HJ; Choi JH; Yoo JH
    J Antimicrob Chemother; 2014 Oct; 69(10):2848-56. PubMed ID: 24928854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Seo YB; Lee J; Kim YK; Lee SS; Lee JA; Kim HY; Uh Y; Kim HS; Song W
    BMC Infect Dis; 2017 Jun; 17(1):404. PubMed ID: 28592240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are beta-lactams related to higher morbidity and mortality in urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli?
    You JH; Kei HW; Lau WC; Wong KY; Marasinghe T; Lee N; Ip M
    J Hosp Infect; 2008 Feb; 68(2):181-3. PubMed ID: 18194826
    [No Abstract]   [Full Text] [Related]  

  • 6. A randomized controlled trial of sitafloxacin vs. ertapenem as a switch therapy after treatment for acute pyelonephritis caused by extended-spectrum β-lactamase-producing Escherichia coli: A pilot study.
    Malaisri C; Phuphuakrat A; Wibulpolprasert A; Santanirand P; Kiertiburanakul S
    J Infect Chemother; 2017 Aug; 23(8):556-562. PubMed ID: 28587974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
    Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
    Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Labombardi VJ; Rojtman A; Tran K
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):313-5. PubMed ID: 17084784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime.
    Pires J; Taracila M; Bethel CR; Doi Y; Kasraian S; Tinguely R; Sendi P; Bonomo RA; Endimiani A
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7483-8. PubMed ID: 26392491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic resistance in adult female patients hospitalized for acute pyelonephritis: rates and predicting factors.
    Etienne M; Van Elslande H; Choplin-Renard J; Pestel-Caron M; Caron F
    Med Mal Infect; 2014 May; 44(5):217-22. PubMed ID: 24787633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study.
    Lee CH; Su LH; Chen FJ; Tang YF; Li CC; Chien CC; Liu JW
    Int J Antimicrob Agents; 2015 Dec; 46(6):610-5. PubMed ID: 26387064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of extended-spectrum β-lactamase production on treatment outcomes of acute pyelonephritis caused by escherichia coli in patients without health care-associated risk factors.
    Park SH; Choi SM; Lee DG; Cho SY; Lee HJ; Choi JK; Choi JH; Yoo JH
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1962-8. PubMed ID: 25583722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-spectrum beta-lactamase-producing bacteria and vesicoureteral reflux in children.
    Ito S; Machida H; Harada T; Teranishi J; Aihara Y; Yokota S
    Pediatr Int; 2010 Feb; 52(1):134-7. PubMed ID: 20158657
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of cefuroxime for women with community-onset acute pyelonephritis caused by cefuroxime-susceptible or -resistant Escherichia coli.
    Chang UI; Kim HW; Wie SH
    Korean J Intern Med; 2016 Jan; 31(1):145-55. PubMed ID: 26767868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intervention study of the association of antibiotic utilization measures with control of extended-spectrum beta-lactamase (ESBL)-producing bacteria.
    Wen Z; Wei X; Xiao Y; Xue F; Hao F; Zhu Y; Ma N; Xiao Y; Wang H
    Microbes Infect; 2010 Sep; 12(10):710-5. PubMed ID: 20457272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity.
    To KK; Lo WU; Chan JF; Tse H; Cheng VC; Ho PL
    Int J Infect Dis; 2013 Feb; 17(2):e120-4. PubMed ID: 23098812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.
    Peña C; Gudiol C; Calatayud L; Tubau F; Domínguez MA; Pujol M; Ariza J; Gudiol F
    J Hosp Infect; 2008 Feb; 68(2):116-22. PubMed ID: 18226420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of extended-spectrum beta-lactamase on acute pyelonephritis treated with empirical ceftriaxone.
    Lee S; Song DY; Cho SH; Kwon KT
    Microb Drug Resist; 2014 Feb; 20(1):39-44. PubMed ID: 23941639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Lee NY; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Diagn Microbiol Infect Dis; 2011 May; 70(1):150-3. PubMed ID: 21398070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes.
    Shanthi M; Sekar U
    J Assoc Physicians India; 2010 Dec; 58 Suppl():41-4. PubMed ID: 21568008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.